Issue of Equity

RNS Number : 2314P

Scancell Holdings Plc

08 February 2023

 

8 February 2023

Scancell Holdings plc

("Scancell" or the "Company")

Exercise of Share Options and Admission of New Ordinary Shares

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies, today announces that it has issued 3,184,630 new ordinary shares of 0.1p each in the share capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options by IchorMedical Systems Inc.at an exercise price of 4.5p per Ordinary Share.

An application for the admission of the 3,184,630 Ordinary Shares to trading on AIM ("Admission") has been made. It is expected that Admission will become effective on or around 13 February 2023.

The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The total number of Ordinary Shares in issue following Admission will be 818,403,461. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:
Scancell Holdings plc	[phone]
Dr Jean-Michel Cosséry, Non-Executive Chairman	[phone]
Professor Lindy Durrant, CEO
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)	[phone]
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker)	[phone]
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
FTI Consulting	[phone]
Simon Conway/Rob Winder/Alex Davis

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

END

 

 

IOEEAFAXEFNDEAA